Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: A reason for the variable efficacy of albendazole and praziquantel?

Journal of Clinical Pharmacology

Volumn 54, Issue 4, 2014, Pages 361-367

  Romo, Matthew L ^a   Carpio, Arturo ^b,c   Kelvin, Elizabeth A ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b UNIVERSIDAD DE CUENCA   (Ecuador)

^c Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

Author keywords

cysticercosis; epilepsy; parasite; pharmacokinetics; taenia solium

Indexed keywords

ALBENDAZOLE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CORTICOSTEROID; HISTAMINE H2 RECEPTOR ANTAGONIST; PHENOBARBITAL; PHENYTOIN; PRAZIQUANTEL; PROTON PUMP INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; BRAIN EDEMA; DRUG BLOOD LEVEL; DRUG EFFICACY; FOOD DRUG INTERACTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; NEUROCYSTICERCOSIS; SEIZURE;

CYSTICERCOSIS; EPILEPSY; PARASITE; PHARMACOKINETICS; TAENIA SOLIUM;

ADRENAL CORTEX HORMONES; ALBENDAZOLE; ANIMALS; ANTHELMINTICS; ANTICONVULSANTS; DRUG INTERACTIONS; HISTAMINE ANTAGONISTS; HUMANS; NEUROCYSTICERCOSIS; PRAZIQUANTEL; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84896119541     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.269     Document Type: Article

References (39)

1. Coyle CM, Mahanty S, Zunt JR, et al. Neurocysticercosis: neglected but not forgotten. PLoS Negl Trop Dis. 2012; 6: e1500.
2. Serpa JA, Clinton White A,. Neurocysticercosis in the United States. Pathog Glob Health. 2012; 106: 256-260.
3. Zammarchi L, Strohmeyer M, Bartalesi F, et al. Epidemiology and management of cysticercosis and taenia solium taeniasis in Europe, systematic review 1990-2011. PLoS ONE. 2013; 8: e69537.
4. Baird RA, Wiebe S, Zunt JR, Halperin JJ, Gronseth G, Roos KL,. Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 80: 1424-1429.
5. Carpio A,. Neurocysticercosis: an update. Lancet Infect Dis. 2002; 2: 751-762. (Pubitemid 35434561)
6. Carpio A, Fleury A, Hauser WA,. Neurocysticercosis: five new things. Neurol Clin Pract. 2013; 3: 118-125.
7. Carpio A, Kelvin EA, Bagiella E, et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2008; 79: 1050-1055.
8. Garcia HH, Pretell EJ, Gilman RH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. 2004; 350: 249-258. (Pubitemid 38067637)
9. Marriner SE, Morris DL, Dickson B, Bogan JA,. Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol. 1986; 30: 705-708. (Pubitemid 16018950)
10. Rawden HC, Kokwaro GO, Ward SA, Edwards G,. Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol. 2000; 49: 313-322. (Pubitemid 30195273)
11. Paredes A, de Campos Lourenco T, Marzal M, et al. In vitro analysis of albendazole sulfoxide enantiomers shows that (+)-(R)-albendazole sulfoxide is the active enantiomer against Taenia solium. Antimicrob Agents Chemother. 2013; 57: 944-949.
12. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM,. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003; 59: 429-442. (Pubitemid 37214951)
13. Jung-Cook H,. Pharmacokinetic variability of anthelmintics: implications for the treatment of neurocysticercosis. Expert Rev Clin Pharmacol. 2012; 5: 21-30.
14. Souhaili-El Amri H, Mothe O, Totis M, et al. Albendazole sulfonation by rat liver cytochrome P-450c. J Pharmacol Exp Ther. 1988; 246: 758-764.
15. Marques MP, Takayanagui OM, Lanchote VL,. Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450. Braz J Med Biol Res. 2002; 35: 261-269. (Pubitemid 34229072)
16. Corti N, Heck A, Rentsch K, et al. Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers. Eur J Clin Pharmacol. 2009; 65: 999-1006.
17. Lanchote VL, Garcia FS, Dreossi SA, Takayanagui OM,. Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. Ther Drug Monit. 2002; 24: 338-345. (Pubitemid 34553197)
18. Castro N, Marquez-Caraveo C, Brundage RC, et al. Population pharmacokinetics of albendazole in patients with neurocysticercosis. Int J Clin Pharmacol Ther. 2009; 47: 679-685.
19. Leopold G, Ungethum W, Groll E, Diekmann HW, Nowak H, Wegner DH,. Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics. Eur J Clin Pharmacol. 1978; 14: 281-291. (Pubitemid 9100345)
20. Lima RM, Ferreira MA, de Jesus Ponte Carvalho TM, et al. Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. Br J Clin Pharmacol. 2011; 71: 528-535.
21. Ridtitid W, Ratsamemonthon K, Mahatthanatrakul W, Wongnawa M,. Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. J Clin Pharm Ther. 2007; 32: 585-593. (Pubitemid 350135111)
22. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M,. Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002; 72: 505-513. (Pubitemid 36237721)
23. Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D,. Enzyme induction with antiepileptic drugs: cause for concern?. Epilepsia. 2013; 54: 11-27.
24. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008; 49: 1239-1276. (Pubitemid 351991390)
25. Jung H, Hurtado M, Medina MT, Sanchez M, Sotelo J,. Dexamethasone increases plasma levels of albendazole. J. Neurol. 1990; 237: 279-280. (Pubitemid 20259983)
26. Takayanagui OM, Lanchote VL, Marques MP, Bonato PS,. Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Ther. Drug Monit. 1997; 19: 51-55. (Pubitemid 28068995)
27. Bittencourt PR, Gracia CM, Martins R, Fernandes AG, Diekmann HW, Jung W,. Phenytoin and carbamazepine decreased oral bioavailability of praziquantel. Neurology. 1992; 42: 492-496.
28. Dachman WD, Adubofour KO, Bikin DS, Johnson CH, Mullin PD, Winograd M,. Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. J. Infect. Dis. 1994; 169: 689-691. (Pubitemid 24063026)
29. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013; 54: 551-563.
30. World Health Organization. Cuadro Nacional de Medicamentos Básicos-Ecuador. Available at. Accessed January 15, 2009: 2014 http://www.who.int/selection-medicines/country-lists/ecu-cuadro-general.pdf.
31. Czock D, Keller F, Rasche FM, Haussler U,. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005; 44: 61-98. (Pubitemid 40096038)
32. Vazquez ML, Jung H, Sotelo J,. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology. 1987; 37: 1561-1562. (Pubitemid 17132348)
33. Nagy J, Schipper HG, Koopmans RP, Butter JJ, Van Boxtel CJ, Kager PA,. Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. Am J Trop Med Hyg. 2002; 66: 260-263. (Pubitemid 34756094)
34. Merino G, Alvarez AI, Prieto JG, Kim RB,. The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metab Dispos. 2002; 30: 365-369. (Pubitemid 34263819)
35. Castro N, Gonzalez-Esquivel D, Medina R, Sotelo J, Jung H,. The influence of cimetidine on plasma levels of praziquantel after a single day therapeutic regimen. Proc West Pharmacol Soc. 1997; 40: 33-34. (Pubitemid 27516546)
36. Mares SS, Jung CH, Lopez AT, Gonzalez-Esquivel DF,. Influence of a Mexican diet on the bioavailability of albendazole. Basic Clin Pharmacol Toxicol. 2005; 97: 122-124. (Pubitemid 41021113)
37. Castro N, Medina R, Sotelo J, Jung H,. Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob Agents Chemother. 2000; 44: 2903-2904.
38. Del Brutto OH, Campos X, Sanchez J, Mosquera A,. Single-day praziquantel versus 1-week albendazole for neurocysticercosis. Neurology. 1999; 52: 1079-1081. (Pubitemid 29161627)
39. Jung H, Hurtado M, Sanchez M, Medina MT, Sotelo J,. Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis. Clin Neuropharmacol. 1990; 13: 559-564.